GC Cell

GC Cell Specializes in Cell Therapy, and in 2007, Its Developed Immunecell-LC Was Approved as an Immunotherapy Drug for Liver Cancer. Immunecell-LC Has Now Completed Phase III Clinical Trials for Liver Cancer and Brain Tumors (Glioblastoma/GBM) and Has Attracted Attention from Research Published in SCI-Level Journals, Investigating Its Use in the Treatment of Liver Cancer, Brain Tumors, and Pancreatic Cancer (Clinical Trials Conducted by Researchers). The Company Is Currently Researching and Developing Next-Generation Cellular Immunotherapy Drugs, CAR-T, and Collaborating with ToolGen to Develop Higher-Performance T-Cell-Based Next-Generation Cancer Immunotherapy Drugs.